MDS Capital Corp., one of North America’s oldest venture capital firms targeting health and life science investments, announced today key management promotions and that, effective immediately, it will be changing its name to Lumira Capital Corp. The management changes include: the promotions of Gerry Brunk (Cambridge, MA), Beni Rovinski (Toronto, ON), and Nandini Tandon (Mountain View, CA) to the role of Managing Director where they will join Brian Underdown (Toronto) who continues in that role; Daniel Hetu (Montreal, Quebec) to the role of Venture Partner; and Jack Jenuth and Charles Trimble to the role of Senior Analysts. The name change to Lumira Capital is the final part of a strategic repositioning to enable the firm to build on its strength as a leading North American investor in biopharmaceutical and medical device companies. The company’s new web site is www.lumiracapital.com.
“These management changes have been in the works for some time and reflect the transition that has been occurring at our firm over the past couple of years as each of these investment team members has established themselves as key contributors to our recent successes and the value creation we have enjoyed with investee partners,” said Peter van der Velden, president and CEO, Lumira Capital.
Commenting further, Peter went on to note, “The management changes, along with our new corporate identity, leverage our past while reflecting who we are today. The completion of this repositioning allows us to concentrate on what we do best – providing the financial, operational and strategic support to our portfolio companies and working with their teams to turn outstanding investment opportunities into outstanding companies in the healthcare and life science sectors. We all share a deep passion with these entrepreneurs for transforming great ideas into innovative products and services for patients and healthcare providers.”
About Lumira Capital Corp.:
Built on a foundation that leverages 18 years of North American healthcare and life science investing, the Lumira Capital team has helped to build over 50 companies during the past five years and manages over $350 million of capital. Recent successes include the acquisitions of Morphotek (by Eisai Co.), Corus Pharma (by Gilead Sciences) and PharmAthene (by Healthcare Acquisition Corp.) as well as the IPOs of Alexza Pharmaceuticals, Replidyne and Pharmasset. Other portfolio companies and recent investments include Archemix, Ception Therapeutics, MAKO Surgical, and Spinal Kinetics. Lumira Capital invests primarily in North American emerging-stage biopharmaceutical and medical device companies. For more information visit the Lumira Capital website at www.lumiracapital.com.